#EULAR2025 Abstr#OP0006. There is no standardised definition for complete renal response in #lupus nephritis. Post-hoc analysis of REGENCY showed Obinutuzumab + SOC was superior to PBO + SOC if endpoints for voclosporin and belimumab RCTs were used. Effect size ~13-16% @RheumNow https://t.co/q8MNAV8XF3

Secukinumab Use in Refractory Giant Cell Arteritis In 2023, the phase 2 TitAIN study showed that the effectiveness and safety of secukinumab in 52 patients with giant cell arteritis (GCA) who had an inadequate response to tocilizumab. While we await the results of a larger https://t.co/pG3aN3o4GZ

T2T in #gout w serum #uric #acid / #urate target SAVES LIVES Study of achievement of target 🎯 ⬇️CVE and death If not achieving Urate <360 T2T also reduced baseline #SUA #EULAR2025 @rheumnow abst#OP0005 https://t.co/ePchJ4vqnU

#Oninutuzumab works in #lupus #nephritis #LN no matter how you vary the #renal #responses Of various definitions of #Complete & #Partial #renal #responses abst#OP0006 #EULAR25 @eular_org @RheumNow Not surprised 😲 https://t.co/Zn2lXkddez

1 shot will do! #symptomatic #Knee #OA given #gene #therapy #intra-#articular Seemed to last up to 104 weeks! But no placebo small safety study but sustained #WOMAC responses Needs large #RCT but v interesting #EULAR2025 @RheumNow @eular_org Abst# POS0492 https://t.co/hqTqBorrbA

Exciting results from ARGO trial: -Phase 2 of Sonelokimab (dual IL-17A-IL17F) nanobody in PsA. -Met primary endpoint of ACR50 at week 12 vs PBO. -62% achieved MDA -48% achieved composite of ACR 70+PASI 100 Looking forward to phase 3 results!!! Abstract #OP0096 #EULAR2025 https://t.co/1D52eG8ReS

So much needed in SLE and pregnancy 1. Risk stratification at diagnosis 2. Pregnancy counseling at dx and >1 y before pregnancy 3. Close collab with GYN necessary 4. Challenging management given gaps in evidence. #EULAR2025 #asktheexpert @RheumNow https://t.co/MXGkKpl452

Biomarker data suggest TNFi non-responders in PsA exhibit upregulation of IL-17F gene signatures after treatment failure. Supports IL-17A/F blockade rationale with bimekizumab in TNFi-experienced patients Abstract#OP0091 @RheumNow . #EULAR2025 https://t.co/CWR6ArDRRW

Real-world study on dual bDMARD plus JAKi or TYK2i combinations in refractory PsA. 22 PsA patients on dual bDMARD + JAKi/TYK2i: •Most common: IL-17i + TYK2i •Total exposure: 8.5–10.5 pt-years •Only mild URIs/stomatitis •Clinical improvements seen in joint/skin domains https://t.co/waDReDqSDE

SPEED RCT: In early PsA with poor prognostic factors, PASDAS at 24wks: •Early TNFi: 3.7 •Combo csDMARDs: 4.1 •Step-up csDMARDs: 4.7 Early TNFi beat step-up by -1.09 (p<0.001); combo csDMARDs also superior (-0.69, p=0.02). Early TNFi benefit sustained at 48wks. Abstract#OP0089 https://t.co/MpazF8BIr2